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1. Introduction
Immunization plays a key role in maintaining human health as it saves millions of lives in 
the most economical way from lethal pathogens and other fatal diseases each year, thanks to 
the advanced development of model vaccines, which are biological preparations containing 
an antigenic agent that resembles a disease-causing microorganism to stimulate the host’s 
immune system, thus providing active acquired immunity to a particular disease and destroy-
ing it [1, 2]. Since Jenner’s pioneering inoculations in the late eighteenth century, vaccines 
have been successfully developed to combat various diseases and each year saved numerous 
lives from, mostly, lethal infections and now also certain cancers [3, 4]. Especially, taking 
advantage of the tools discovered in microbiology and immunology, vaccines have recently 
obtained great achievements as demonstrated by their successful performances in conquering 
some formidable pathogens, such as smallpox and rabies, which are used to claim many lives. 
However, the list of pathogens for which there exist no vaccines is still long, and, in particular, 
many pathogens, such as human immunodeficiency virus (HIV), herpes simplex virus (HSV), 
and Ebola virus (EBV), are still posing a big threat to human life, therefore needing urgently 
the effective products to cope with their infections [5].
Vaccines can stimulate the host immune system to develop an armament of immunity 
capable of clearing the abnormalities after administration, because they are developed with 
the antigenic components that are featured by pathogens or neoplasms and usually include 
three types: the live attenuated microbes, killed microbes, and just purified antigens (Ags) of 
microbes or neoplasms [6]. The former two consisting of live attenuated or killed microbes 
are the conventional vaccines with high immunogenicity but, unfortunately, are also linked 
to a relatively poor safety profile as they possess the potential to revert the virulence and 
induce the drifted immune responses leading to incontrollable immunity as well as unaccept-
able inflammations. In contrast, the third one with purified Ags, called a subunit vaccine, has 
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defined components to induce immune responses aiming just at the matched targets causing 
few safety concerns and thus can be employed to fight the infectious pathogens as well as 
malignant neoplasms that are carrying the identical Ags [7]. Presently, subunit vaccines are 
attracting more and more research interests owing to also their diverse applications, adaptive 
functions, and numerous advantages over the whole microbe-based conventional ones, and 
these aspects may well be comprehensively summarized as follows [8]:
1. Their defined noninfectious components effectively confine capricious reversion to viru-
lence while reducing significantly the risk of allergic or autoimmune response [9].
2. Their production may avoid the use of dangerous microorganisms but may be carried out 
with solid-phase peptide synthesis in a reproducible, scalable, and economical manner, 
providing an alternative tool to obtain products to conquer certain pathogens that are prob-
lematic to culture (e.g., sporozoites for malaria vaccines) for attenuation of virulence [10].
3. Ags in subunit vaccines are generally water-soluble allowing them to form a solution 
together with cryoprotectants such as disaccharide, followed by freeze-drying into the sta-
ble anhydrous fitting storage and transportation in a controlled temperature chain (CTC) 
or completely at room temperature [11].
4. Also, subunit vaccines can be tailored with certain pathogen-/damage-associated molecu-
lar patterns (PAMP/DAMP) to be recognized by APCs for efficient activation, even includ-
ing several peptide epitopes targeting different stages in the life cycle of a pathogen [8, 
12, 13]; obviously, this is particularly useful for developing anticancer vaccines, wherein 
whole protein can hardly be used due to its similarity to the endogenous human proteins 
and carcinogenic properties [14].
However, unfortunately, subunit vaccines often have a rather weak immunogenicity, due to 
lack of the immunostimulatory components broadly shared by pathogens while being dis-
tinguishable from host molecules, which are collectively referred to as pathogen-associated 
molecular patterns (PAMPs) [15] able to bind to and trigger mammalian pattern recognition 
receptors (PRRs), such as the TLRs (toll-like receptors), NOD-like receptors (the nucleotide-
binding oligomerization domain-like receptors), RIG-I-like receptors (retinoic acid-inducible 
gene-I-like receptor), and C-type lectin receptors, thus playing an adjuvant role to activate the 
innate immunity, followed by sponsoring a series of adaptive reactions involved in establish-
ing the Ag-specific immunity [16].
Thus, while subunit vaccines are regarded as a safer product than the whole microbe-based 
conventional ones, they are also poorly immunogenic and often require an adjuvant or a 
vaccine adjuvant-delivery system (VADS) able to target the professional Ag-presenting cells 
(APCs), such as dendritic cells (DCs) and macrophages (MPs), to make full use of Ags and 
boost their immunostimulatory activity [17–21]. A vaccine adjuvant is defined as a non-spe-
cific immunopotentiating substance but capable of enhancing the body’s immune response to 
the Ag or changing the type of immune responses, when administered either alone in advance 
or simultaneously together with the vaccine Ag. Although its immune-boosting mechanisms 
remain elusive, an adjuvant is argued to fulfill the functions involving, roughly, two aspects: 
(1) generating damages on host cells/tissues, thus sending dangerous signals out to activate 
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the immune system and (2) binding to PRRs and exciting the innate immune cells, such as DCs, 
MPs, histiocytes, and mast cells, which subsequently initiate the innate immune responses to 
sponsor the subsequent adaptive immune responses [22, 23]. Accordingly, vaccine adjuvants 
may well be classified into two types: type I, the natural or synthetic substances with intrinsic 
adjuvanticity, squalene/squalane, saponin, chitosan, hyaluronic acid (HA), and various pat-
tern recognition receptor agonists (PRRas) and type II, the micron-/nanometer-sized particles, 
such as alum (insoluble aluminum salt) and vaccine adjuvant-delivery systems (VADSs) 
that are carriers engineered with at least two fundamental functions, i.e., adjuvanticity and 
Ag delivery. VADSs are usually constructed with a variety of biocompatible nanoparticles 
(NPs) made of various organic or inorganic materials, such as liposomes, ISCOMs (immune- 
stimulating complexes), polymeric NPs, VLPs (virus-like particles), emulsions, and the 
inorganic NPs, which are often incorporated with type I substances to further enhance their 
immunopotentiating functions [6, 24].
2. Immune responses for establishing the Ag-specific immunity
Always confronting and fighting with dangerous pathogens, mammals have gradually 
evolved to form a complexed defensive immune system, which can be classified into 
subsystems of the innate immune system versus the adaptive immune system [25]. The 
innate immune system consists of surface barriers, complement system, and various leu-
kocytes including the phagocytes (macrophages, neutrophils, and dendritic cells), innate 
lymphoid cells, mast cells, eosinophils, basophils, and natural killer cells, which fulfill the 
role of non-specific immune defenses responding to pathogens in a generic way conferring 
short-lasting immunity against a pathogen [26]. For this, mammalian leukocytes are evo-
lutionarily equipped with receptors able to recognize certain pathogen components bear-
ing specific structural characteristics, such as free bacterial and viral DNA, lipoproteins, 
lipopolysaccharides, and flagellins, which are pathogen-/danger-associated molecular 
patterns (PAMPs/DAMPs) [27]. These functional receptors are expressed by host immune 
cells, such as TLR1 to TLR13, NOD-like receptors, RIG-I-like receptors, and C-type lectin 
of mannose receptors, which are collectively called pattern recognition receptors (PRRs), 
with each capable of selectively binding to specific PAMPs/DAMPs of pathogens, leading 
to the activation of the innate immune cells, which subsequently sponsor the immuno-
responses of the whole immune system, thus providing the bases for defending against 
pathogens [28].
However, establishing the Ag-specific immunity for defending against pathogens involves 
several complex immune pathways going with the orchestration of numerous immunocytes, 
cytokines, and chemokines and starts, usually, upon the activation of APCs for innate immune 
reactions triggered by their internalized antigenic substances (Ags) that they distinguished as 
dangerous signals through, in most cases, the process of PRR-PAMP/DAMP recognition [23]. 
Briefly, positioned at the frontier of pathogen/vaccine recognition, APCs first take up, in a 
size-dependent manner (e.g., NPs with a size of <150 nm are taken up by APCs by clathrin-
mediated endocytosis, while microparticles by phagocytosis); the Ags appeared in peripheral 
tissues or in the draining lymph nodes (dLNs), wherein APCs will mature and process the 
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internalized Ags into pieces with epitopes, which are finally bound to MHC-II (major histo-
compatibility complex II) and/or MHC-I and displayed on cell surfaces for presentation to T 
cells [29]. MHC-I molecules are assembled in the endoplasmic reticulum (ER) with stabiliza-
tion by chaperone proteins (including calreticulin, Erp57, protein disulfide isomerase (PDI), 
and tapasin) and are loaded, under tapasin mediation, with exogenous (viral or self-origi-
nated) Ags, which are translocated from the cytoplasm into the ER by TAP (transporter associ-
ated with antigen presentation) for presentation via T-cell receptors (TCRs) to CD8+ T cells for 
their activation [30]. MHC-II molecules are assembled in the ER, stabilized by an invariant 
chain (Ii) and transported through the Golgi to fuse with a late endosome forming the MHC-II 
endosome compartment (MIIC) with an acidic interior containing proteases cathepsin S and 
cathepsin L, which when activated will digest Ii, leaving in the peptide-binding groove of 
the MHC-II a residual class II-associated Ii peptide (CLiP), which later is exchanged for an 
antigenic peptide (usually exogenous Ags) derived from a protein degraded in the endosomal 
pathway for presentation via T-cell receptors (TCRs) to CD4+ T cells for their activation [30].
During Ag presentation, a substantial number of various signaling cytokines such as inter-
leukins and interferons, as well as chemokines, are secreted by matured APCs and other 
immunocytes to promote the MHC-II-Ag epitope-triggered CD4+ T-cell differentiation into 
either T-helper type-1 (Th1) cells that will secrete IFN-γ, IL-12, and IL-2 or Th2 cells that will 
secrete IL-4. Then, Th1 cells will further secrete IL-12 and IFN-γ facilitating the MHC-I-Ag 
epitope-triggered CD8+ T cells to proliferate and differentiate into the Ag-specific cytotoxic 
T lymphocytes (CTLs), thus establishing the cellular immunity while forming memory T 
cells [31, 32]. Meanwhile, the Th2 cells mature to favor Ag presentation to B cells via B cell 
receptors (BCRs) and to secrete IL-4, IL-6, and IL-10, which are also beneficial for promot-
ing the Ag-activated B cells to proliferate and differentiate into plasma cells to produce the 
anti-Ag antibodies, establishing finally the humoral immunity while forming memory B cells 
[33]. With memory T and B cells, upon encountering pathogens, both humoral and cellular 
immunity can be rapidly established; while humoral immunity neutralizes the extracellular 
pathogens during or before the infection and thus is fitting for the prophylaxis of pathogen 
invasion, cellular immunity is mainly responsible for destroying already infected or abnormal 
human cells and therefore may be employed for the clearance of the cell-hidden pathogens or 
malignant tumors, through specialized TCR recognition of the precisely matched Ags nestled 
in the groove of MHC-I on cells [12].
3. Immunization: vaccine adjuvant-delivery system and strategies
In designing the NP-based VADSs, what should be emphasized is that the differently sourced 
Ags are processed and trigger immune signal transduction in different ways [34]. Usually, the 
internalized exogenous Ags delivered by NPs are processed intracellularly by APCs into small 
antigens just inside the endolysosomal vesicles and then loaded favorably on MHC-II molecules, 
leading to activation of CD4+ T cells to differentiate into Th2 cells, which will further stimulate 
production of antibodies by B cells [8]. In contrast, the endogenous Ags, such as viral Ags, cancer 
components, and intracellular-degraded proteins, are usually presented in the cytosol and often 
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loaded on MHC-I molecules, allowing for further activation of CD8+ T cells to differentiate into 
CTLs and to engender cellular immunity [35]. However, it is generally believed that, though not 
well understood, provided the exogenous Ags are transported via membrane fusion or other 
ways engendering Ag lysosome escape into the cytosol, they can also be processed via MHC-I 
presentation in just the same manner as that for endogenous Ags, and this process is known as 
Ag cross presentation [36]. This provides the basis for designing the NP-based VADS which are 
exogenous particles favoring of inducing humoral immunity but may be adorned with materials 
that can facilitate APC internalization in the membrane fusion manner or promote endolysosome 
escape and cross presentation of Ags to induce cellular immunity, thus expanding VADS into 
various applications, including mainly prophylaxis of infections, treatment of autoimmunity dis-
eases, and immunotherapy of cancer [12]. In particular, as a multifunctional VADS, NPs modified 
with different materials with intrinsic and specific adjuvanticity, such as TLRas (e.g., MPL and 
CpG ODN), squalene, and saponin (e.g., water-soluble QS-21), though showing individually dis-
tinctive features, share some key characteristics in immune-boosting functions [37]. Summarily, 
these multifunctional Nps as a VADS trigger immunoresponses with features including, mainly, 
early activation, though at different levels, of innate immunity, which will subsequently trans-
late into strong antibody and cellular responses to the delivered antigens [5]; a wide breadth of 
adaptive immunity is able to confer protections against heterovariants of pathogens; for example, 
vaccines delivered by liposomes containing MPL can defend against influenza viruses or human 
papillomavirus (HPV) strains that are not contained in the vaccines [38]; significant enhance-
ment of the immunoresponses and the efficacy of vaccines in the elderly who show a waning 
immune responsiveness to infection and vaccination, as shown for vaccines formulated with 
MPL-liposomes against herpes zoster virus [39]. These results, together with the feasibility of 
large-scale manufacture and the track records of acceptable safety profiles of many liposome-
based medications, pave the way for developing novel multifunctional liposomes to be used as a 
VADS for producing the vaccine products fitting humans of different age against infections with 
a high toll of morbidity and mortality.
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